Weekly Cardiology Research Analysis
This week’s cardiology literature emphasizes practice-changing interventional strategies, imaging-guided device personalization, and health-system–level benefits of cardiometabolic therapy. A high-quality RCT meta-analysis supports drug-coated balloons over drug-eluting stents for small-vessel coronary disease. Imaging guidance with 4D CMR improved CRT response in a randomized trial, and semaglutide reduced total hospitalizations and hospital days in a large RCT cohort with established CVD and o
Summary
This week’s cardiology literature emphasizes practice-changing interventional strategies, imaging-guided device personalization, and health-system–level benefits of cardiometabolic therapy. A high-quality RCT meta-analysis supports drug-coated balloons over drug-eluting stents for small-vessel coronary disease. Imaging guidance with 4D CMR improved CRT response in a randomized trial, and semaglutide reduced total hospitalizations and hospital days in a large RCT cohort with established CVD and obesity.
Selected Articles
1. Drug-Coated Balloons Versus Drug-Eluting Stents in Small Vessel De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis.
A PROSPERO-registered, PRISMA-compliant meta-analysis of six randomized trials (n=1,876) showed that drug-coated balloons (DCBs) reduced MACE (RR 0.83), TLR (RR 0.68), angiographic restenosis (RR 0.76), MI (RR 0.81), and all-cause mortality (RR 0.79) versus drug-eluting stents in de novo small-vessel coronary disease (reference vessel diameter ≤2.75 mm), with no heterogeneity across endpoints.
Impact: Provides randomized-trial–level evidence that challenges a stent-first paradigm in small-vessel disease by demonstrating consistent benefit of a non-implant, local drug-delivery strategy across hard endpoints.
Clinical Implications: For appropriately selected small-vessel lesions (≤2.75 mm), consider DCB-first PCI strategies to reduce restenosis-driven reinterventions and potentially shorten DAPT; require lesion preparation and operator expertise for optimal results.
Key Findings
- Meta-analysis of 6 RCTs (n=1,876) comparing DCB vs DES in de novo small-vessel CAD.
- DCB reduced MACE (RR 0.83), TLR (RR 0.68), angiographic restenosis (RR 0.76), MI (RR 0.81), and all-cause mortality (RR 0.79).
- No heterogeneity across endpoints (I²=0%); sensitivity analyses (RVD ≤2.75 mm) unchanged.
2. 4D Digital Heart Model-Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial.
In a multicenter randomized trial (n=202), a web-app implementing 4D CMR phenomics that integrates scar distribution, regional systolic delay, and interlead distance increased the proportion of CRT recipients achieving ≥5% absolute LVEF improvement at 6 months (65.7% vs 52.1%; RR 1.80) without longer procedures or added complications.
Impact: A randomized demonstration that phenotype-driven, image-guided lead targeting improves CRT physiologic response addresses a major cause of CRT nonresponse and is directly translatable via a practical web tool.
Clinical Implications: Centers with CMR capability should consider integrating 4D phenomics planning to personalize LV/RV lead placement for CRT to improve response rates; further trials powered for clinical endpoints are warranted.
Key Findings
- 4DPcmr-guided implantation achieved ≥5% LVEF increase at 6 months in 65.7% vs 52.1% (RR 1.80).
- No increase in procedural time or complications with the imaging-guided approach.
- Target selection algorithm combined scar burden, maximal regional systolic delay, and maximal interlead distance.
3. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
Prespecified exploratory analysis of SELECT (n=17,604; median follow-up 41.8 months) found once-weekly semaglutide 2.4 mg reduced total hospital admissions (18.3 vs 20.4 per 100 patient-years; mean ratio 0.90) and total hospital days (157.2 vs 176.2 days per 100 patient-years; RR 0.89) versus placebo, including admissions for serious adverse events, with consistent effects across subgroups.
Impact: Extends the benefits of a GLP-1 receptor agonist beyond MACE reduction to reduced healthcare utilization (admissions and bed-days) in a large, multinational randomized cohort without diabetes, with implications for population health and cost.
Clinical Implications: For patients with established CVD and overweight/obesity (without diabetes), semaglutide may be considered to reduce hospitalization burden as well as cardiovascular risk; health systems should evaluate implications for resource use and cost-effectiveness.
Key Findings
- Total hospitalizations: 18.3 vs 20.4 per 100 patient-years with semaglutide vs placebo (MR 0.90; 95% CI 0.85–0.95).
- Days hospitalized for any cause: 157.2 vs 176.2 per 100 patient-years (RR 0.89; 95% CI 0.82–0.98).
- Reductions persisted for admissions related to serious adverse events and across tested subgroups.